Oxford Immunotec Global PLC (NASDAQ:OXFD) CEO Peter Wrighton-Smith sold 20,000 shares of Oxford Immunotec Global stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $14.92, for a total transaction of $298,400.00. Following the transaction, the chief executive officer now owns 404,538 shares of the company’s stock, valued at approximately $6,035,706.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Peter Wrighton-Smith also recently made the following trade(s):
- On Friday, August 16th, Peter Wrighton-Smith sold 10,000 shares of Oxford Immunotec Global stock. The stock was sold at an average price of $13.86, for a total transaction of $138,600.00.
Oxford Immunotec Global stock traded up $0.28 during trading on Wednesday, reaching $17.19. The company had a trading volume of 168,900 shares, compared to its average volume of 175,424. Oxford Immunotec Global PLC has a 12-month low of $11.88 and a 12-month high of $18.60. The stock’s 50 day moving average price is $13.82 and its two-hundred day moving average price is $14.80. The firm has a market capitalization of $390.39 million, a price-to-earnings ratio of 33.71 and a beta of 0.37. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.76 and a current ratio of 13.35.
Institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP purchased a new stake in Oxford Immunotec Global in the second quarter valued at approximately $173,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Oxford Immunotec Global during the second quarter worth approximately $805,000. Marshall Wace LLP purchased a new stake in Oxford Immunotec Global during the first quarter worth approximately $1,185,000. Senvest Management LLC grew its stake in Oxford Immunotec Global by 32.5% during the second quarter. Senvest Management LLC now owns 490,902 shares of the company’s stock worth $6,755,000 after buying an additional 120,329 shares during the period. Finally, C M Bidwell & Associates Ltd. purchased a new stake in Oxford Immunotec Global during the second quarter worth approximately $93,000. Hedge funds and other institutional investors own 94.09% of the company’s stock.
A number of equities analysts have issued reports on OXFD shares. TheStreet cut shares of Oxford Immunotec Global from a “c-” rating to a “d+” rating in a research report on Monday, July 15th. Zacks Investment Research cut shares of Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Piper Jaffray Companies set a $20.00 target price on shares of Oxford Immunotec Global and gave the stock a “buy” rating in a research report on Wednesday, September 18th. ValuEngine upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, BidaskClub upgraded shares of Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a research report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $19.00.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Read More: What does an equal weight rating mean?
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.